Literature DB >> 19022819

The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications.

T Weichhart1, M D Säemann.   

Abstract

The phosphatidylinositol-3 kinases (PI3Ks) and the mammalian target of rapamycin (mTOR) pathway have long been recognised as critically regulating metabolism, growth or survival. Recent data indicate that these molecules are also integral players in coordinating defence mechanisms in the innate immune system. In this respect, PI3K and mTOR positively regulate immune cell activation in neutrophils and mast cells. In plasmacytoid dendritic cells, these pathways have recently emerged as important regulators for type I interferon production via activation of the interferon-regulatory factor 7. Interestingly, in myeloid immune cells, PI3K and mTOR seem to constrain full immune cell activation by upregulation of the key anti-inflammatory cytokine interleukin 10 and inhibition of proinflammatory cytokines. These new insights into innate immune cell regulation may pave the way for manipulating distinct features of the innate immune system for therapeutic treatment of various inflammatory diseases and for implementation of improved vaccination strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19022819     DOI: 10.1136/ard.2008.098459

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  110 in total

Review 1.  New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome.

Authors:  David T Teachey
Journal:  Curr Opin Pediatr       Date:  2012-02       Impact factor: 2.856

Review 2.  Regulation of immune cell development through soluble inositol-1,3,4,5-tetrakisphosphate.

Authors:  Karsten Sauer; Michael P Cooke
Journal:  Nat Rev Immunol       Date:  2010-04       Impact factor: 53.106

3.  Suppression of CpG-ODN-mediated IFNα and TNFα response in human plasmacytoid dendritic cells (pDC) by cannabinoid receptor 2 (CB2)-specific agonists.

Authors:  Joseph E Henriquez; Robert B Crawford; Norbert E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  2019-02-23       Impact factor: 4.219

Review 4.  Kinase AKT controls innate immune cell development and function.

Authors:  Yan Zhang; Xiao Wang; Hui Yang; Huanrong Liu; Yun Lu; Limei Han; Guangwei Liu
Journal:  Immunology       Date:  2013-10       Impact factor: 7.397

5.  Microbiota-Derived Metabolic Factors Reduce Campylobacteriosis in Mice.

Authors:  Xiaolun Sun; Kathryn Winglee; Raad Z Gharaibeh; Josee Gauthier; Zhen He; Prabhanshu Tripathi; Dorina Avram; Steven Bruner; Anthony Fodor; Christian Jobin
Journal:  Gastroenterology       Date:  2018-02-01       Impact factor: 22.682

6.  Akt Cys-310-targeted inhibition by hydroxylated benzene derivatives is tightly linked to their immunosuppressive effects.

Authors:  Ji Yeon Lee; Yong Gyu Lee; Jaehwi Lee; Keum-Jin Yang; Ae Ra Kim; Joo Young Kim; Moo-Ho Won; Jongsun Park; Byong Chul Yoo; Sanghee Kim; Won-Jea Cho; Jae Youl Cho
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

7.  Phosphatidylinositol-3-kinase activity during in vitro dendritic cell generation determines suppressive or stimulatory capacity.

Authors:  Valentina Di Caro; Antonella D'Anneo; Brett Phillips; Carl Engman; Jo Harnaha; Massimo Trucco; Nick Giannoukakis
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

Review 8.  Pleiotropic regulations of neutrophil receptors response to sepsis.

Authors:  Huafeng Zhang; Bingwei Sun
Journal:  Inflamm Res       Date:  2016-09-30       Impact factor: 4.575

9.  Phosphatidylinositol-(3,4,5)-Trisphosphate Induces Phagocytosis of Nonmotile Pseudomonas aeruginosa.

Authors:  Sally Demirdjian; Daniel Hopkins; Hector Sanchez; Michael Libre; Scott A Gerber; Brent Berwin
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

Review 10.  Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa.

Authors:  Rustin R Lovewell; Yash R Patankar; Brent Berwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-01-24       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.